Roivant Sciences Ltd. (ROIV) News
Follow Roivant Sciences Ltd. (ROIV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 37 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: IMVT-1402 halted for cutaneous lupus and FcRn programs
Roivant Sciences Ltd. (NASDAQ:ROIV) halted IMVT-1402’s cutaneous lupus program after a 12-week trial missed its primary endpoint, sending shares lower, while refocusing the asset on other autoimmune uses and prioritizing
EQUITY | Sep 28, 2026, 11:04 AM UTC
L
Roivant (ROIV) Halts CLE Program After IMVT-1402 Misses Primary Endpoint
Roivant said Immunovant’s IMVT-1402 proof-of-concept study in cutaneous lupus erythematosus did not meet the Week 12 primary endpoint, and development in CLE will stop. Other autoimmune indications for IMVT-1402 remain i
NEWS | Sep 23, 2026, 11:03 AM UTC
L
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
BASEL, Switzerland and LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Roivant NASDAQ:ROIV today announced topline results from Period 1 of Immunovant’s proof-of-concept trial evaluating IMVT-1402 (imeroprubart)
NEWS | Sep 23, 2026, 11:03 AM UTC
L
ROIV: Robust pipeline advances and strong financials set the stage for multiple upcoming launches
Strong financials and pipeline momentum highlighted, with recent FDA approval for LISRAYA and best-in-class data for mosliciguat in PH-ILD. Multiple late-stage trials and launches are expected in the next year, targeting
REGULATION | Sep 10, 2026, 02:55 PM UTC
L
ROIV: Mosliciguat's breakthrough data and brepocitinib's promising DM launch drive major pipeline momentum
Mosliciguat delivered record efficacy in pulmonary hypertension, prompting plans for broader indications and rapid phase III enrollment. Brepocitinib's DM launch is progressing steadily, with strong physician enthusiasm
EQUITY | Sep 09, 2026, 07:01 PM UTC
L
ROIV: Mosliciguat's breakthrough data and brepocitinib's strong launch drive broad pipeline momentum
Mosliciguat delivered record efficacy in pulmonary hypertension, prompting broad indication expansion and rapid phase III initiation. Brepocitinib's DM launch is progressing steadily, with strong physician interest and s
EQUITY | Sep 09, 2026, 06:15 PM UTC
L
Roivant Sciences price target raised to $55 from $50 by TD Cowen
TD Cowen raised its price target on Roivant Sciences to $55.00 per share from $50.00 while maintaining a Buy rating.
EQUITY | Sep 09, 2026, 02:44 PM UTC
L
Guggenheim raises Roivant Sciences price target to $46 from $42
Guggenheim raised its price target for Roivant Sciences to $46.00 from $42.00 and maintained a Buy rating, per Benzinga.
EQUITY | Sep 09, 2026, 01:30 PM UTC
L
HC Wainwright keeps Roivant at Buy; raises PT to $47
HC Wainwright & Co. maintained Roivant Sciences at Buy and raised its price target to $47.00 per share from $41.00, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 05:58 PM UTC
M
Roivant and Pharvaris surge to record highs on positive trial results
Roivant Sciences (ROIV) and Pharvaris (PHVS) hit all-time highs after reporting positive results for experimental therapies across different trial phases. ROIV was up more than 20% and PHVS was up nearly 8%.
EQUITY | Sep 08, 2026, 05:54 PM UTC
M
Roivant stock jumps as lung drug meets mid-stage goal
Roivant Sciences’ experimental mosliciguat met the mid-stage trial’s main goal for patients with high blood pressure in the arteries of the lungs and heart, prompting a surge in its shares.
EQUITY | Sep 08, 2026, 04:36 PM UTC
L
Jefferies maintains Roivant Sciences at Buy; PT raised to $52
Jefferies maintains a Buy rating on Roivant Sciences and raises its price target to $52.00 per share from $42.00, per Benzinga/TradingView News.
EQUITY | Sep 08, 2026, 03:55 PM UTC
M
ROIV data and LISRAYA launch cited as autoimmune momentum drivers
TradingView News cites PHocus phase IIb data in PH-ILD showing record efficacy, prompting rapid phase III enrollment. It also says LISRAYA launched for dermatomyositis with strong clinical and steroid-sparing benefits, w
EQUITY | Sep 08, 2026, 03:15 PM UTC
M
Roivant’s mosliciguat shows record PVR reduction in PH-ILD trial
Roivant’s PHocus study in PH-ILD found mosliciguat delivered a record 56.3% reduction in PVR, with significant six-minute walk and NT-proBNP improvements and a favorable safety profile, consistent across subgroups. A pha
EQUITY | Sep 08, 2026, 01:51 PM UTC
M
Roivant says mosliciguat cut pulmonary vascular resistance in Phase 2
Roivant said mosliciguat produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance in the Phase 2 PHocus study. It also cited a 35.2m 6MWD gain and said Phase 3 is underway.
REGULATION | Sep 08, 2026, 01:23 PM UTC
M
ROIV’s mosliciguat advances to phase III in PH-ILD
Phase IIb PHocus study in PH-ILD said mosliciguat delivered a record 56.3% reduction in PVR, with significant and sustained six-minute walk distance improvements, and robust safety and tolerability. Benefits were consist
EQUITY | Sep 08, 2026, 01:08 PM UTC
M
Roivant drug Mosliciguat meets Phase 2 goal; ROIV shares jump premarket
Roivant’s experimental lung disease drug Mosliciguat met the primary goal in a key Phase 2 study, driving ROIV shares up 22% in pre-market trading.
EQUITY | Sep 08, 2026, 11:51 AM UTC
M
ROIV’s mosliciguat advances to phase 3 in PH-ILD
Mosliciguat showed a 56.3% reduction in PVR and improvements in 6MWD and NT-proBNP in PH-ILD patients, with favorable safety and once-daily dosing. A phase 3 trial is underway to evaluate efficacy and safety further.
EQUITY | Sep 08, 2026, 11:37 AM UTC
M
Roivant drug meets mid-stage goals; ROIV shares jump premarket
Roivant (ROIV) said its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 20% in premarket trading.
EQUITY | Sep 08, 2026, 10:59 AM UTC
M
Roivant Sciences shares jump after positive mid-stage trial results
Roivant Sciences shares rose 22% to $42.68 after the company disclosed positive results from a mid-stage trial evaluating its pulmonary hypertension treatment.
EQUITY | Sep 08, 2026, 10:51 AM UTC
M
Roivant announces positive Phase 2 PHocus mosliciguat results
Roivant says it has positive results from its Phase 2 PHocus trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also unveils an ongoing Phase 3 PHrontier study.
EQUITY | Sep 08, 2026, 10:07 AM UTC
M
Roivant gets FDA approval for LISRAYA brepocitinib in dermatomyositis
Roivant Sciences Ltd. said the FDA approved LISRAYA (brepocitinib) 30 mg for adult dermatomyositis following Phase 3 VALOR results showing clinical and functional gains.
GEOPOLITICS | Sep 07, 2026, 11:22 AM UTC
L
Roivant to present PHocus Phase 2 topline results for mosliciguat
Roivant and Pulmovant said results from the Phase 2 PHocus study of mosliciguat in pulmonary hypertension associated with interstitial lung disease will be presented at ERS Congress 2026 on Tuesday, Sept. 8, 2026, plus a
GEOPOLITICS | Sep 06, 2026, 05:07 AM UTC
L
Roivant launches LISRAYA commercially at $35,000 per 30-count
Roivant Sciences launches LISRAYA commercially at $35,000 per 30-count, alongside a presentation on FDA approval.
REGULATION | Aug 28, 2026, 08:34 PM UTC
M
ROIV FDA approval for oral LISRAYA dermatomyositis therapy
ROIV said the FDA approved LISRAYA as the first oral-targeted therapy for dermatomyositis, launching immediately.
REGULATION | Aug 28, 2026, 02:59 PM UTC
M
GILD, ROIV win FDA nod in weekly biotech buzz
Weekly Buzz highlights FDA nods for GILD and ROIV; also cites a BHVN/LLY deal and SYRE missing a monotherapy goal.
REGULATION | Aug 28, 2026, 02:57 PM UTC
M
ROIV FDA approval of LISRAYA for dermatomyositis; launches immediately
ROIV says the FDA approved LISRAYA as the first oral targeted therapy for dermatomyositis, with launch immediately.
REGULATION | Aug 28, 2026, 01:48 PM UTC
M
Roivant and Priovant launch rare disease drug Lisraya at $35,000/month
Roivant and Priovant launched newly approved rare disease drug Lisraya at $35,000 a month.
EQUITY | Aug 28, 2026, 01:42 PM UTC
L
Roivant prices rare disease drug Lisraya at $35,000/month
Roivant set the price for its rare disease drug Lisraya at $35,000 a month.
EQUITY | Aug 28, 2026, 12:13 PM UTC
M
FDA approval for ROIV’s LISRAYA dermatomyositis therapy
FDA approves LISRAYA as the first targeted oral therapy for dermatomyositis, with launch immediately.
REGULATION | Aug 28, 2026, 12:09 PM UTC
L
HC Wainwright maintains ROIV $41 price target
HC Wainwright & Co. maintained its price target for Roivant Sciences at $41.00 per share.
EQUITY | Aug 28, 2026, 11:56 AM UTC
M
Roivant announces FDA approval and U.S. availability of LISRAYA
Roivant Sciences announced FDA approval and U.S. availability of LISRAYA for dermatomyositis.
REGULATION | Aug 27, 2026, 09:35 PM UTC
M
ROIV gets FDA approval for targeted oral dermatomyositis therapy
ROIV says the FDA approved LISRAYA as the first targeted oral therapy for adult dermatomyositis.
REGULATION | Aug 27, 2026, 09:04 PM UTC
M
US FDA approves Roivant-Priovant skin disease drug
US FDA approved Roivant-Priovant’s skin disease drug.
REGULATION | Aug 27, 2026, 07:40 PM UTC
M
Roivant announces FDA approval for LISRAYA in dermatomyositis
Roivant said the FDA approved LISRAYA (brepocitinib) for adults with dermatomyositis and it is now available in the U.S.
REGULATION | Aug 27, 2026, 07:37 PM UTC
M
JAMA Dermatology publishes Phase 3 VALOR brepocitinib skin outcomes
JAMA Dermatology published skin-specific outcomes from the Phase 3 VALOR trial of brepocitinib in dermatomyositis, per TradingView News.
EQUITY | Aug 26, 2026, 03:17 PM UTC
M
ARGX: H.C. Wainwright Remains Bullish
H.C. Wainwright remains bullish on Argenx despite changes to the Phase 3 Vyvgart study in myositis, citing strong prospects in immune-mediated necrotizing myopathy
EQUITY | Jun 25, 2026, 05:57 PM UTC